Gene Dose of Apolipoprotein E Type 4 Allele and the Risk of Alzheimer's Disease in Late Onset Families
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
The apolipoprotein E type 4 allele ( APOE -ε4) is genetically associated with the common late onset familial and sporadic forms of Alzheimer's disease (AD). Risk for AD increased from 20% to 90% and mean age at onset decreased from 84 to 68 years with increasing number of APOE -ε4 alleles in 42 families with late onset AD. Thus APOE -ε4 gene dose is a major risk factor for late onset AD and, in these families, homozygosity for APOE -ε4 was virtually sufficient to cause AD by age 80.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Common variants of the apolipoprotein E gene (APOE) influence the risk of Alzheimer’s disease: APOE4 is linked to high risk, APOE3 is considered to confer a neutral risk, and APOE2 is associated with relative protection.2–5”
From APOE3 Christchurch Heterozygosity and Autosomal Dominant Alzheimer’s Disease (2024) · cites this paper as [3]
Experimental — accuracy not yet measuredIn the citing paper
“Compared to the most common APOE3/3 genotype, each additional copy of the APOE4 allele is associated with a higher risk of Alzheimer’s dementia and a younger mean age at dementia onset, such that APOE4 homozygotes are at the highest risk”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [3]
In the citing paper
“while the presence of one or two copies of the APOE2 allele is associated with a lower risk of Alzheimer’s dementia and an older mean age at dementia onset1–4.”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [3]
In the citing paper
“such that APOE4 homozygotes are at the highest risk”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [3]
In the citing paper
“Apolipoprotein E (APOE), the major susceptibility gene for late-onset Alzheimer’s disease (AD), has three common alleles (APOE2, 3, and 4), giving rise to six genotypes (APOE2/2, 2/3, 3/3, 2/4, 3/4, and 4/4).”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [3]
91 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Cox, D. R., & Oakes, D. (2018) · Chapman & Hall/CRC eBooks · doi:10.1201/9781315137438 · Cited by 6,234
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
Self-citationStrittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1977 · Cited by 4,268
Self-citationAssociation of apolipoprotein E allele ϵ4 with late‐onset familial and sporadic Alzheimer's disease
Saunders, A. M., Strittmatter, W. J., Schmechel, D., St. George-Hyslop, P. H., Pericak-Vance, M. A., Joo, S. H., Rosi, B. L., Gusella, J. F., Crapper-MacLachlan, D. R., Alberts, M. J., et al. (1993) · Neurology · doi:10.1212/wnl.43.8.1467 · Cited by 3,786
Self-citationMiller, R. G. (1981) · Cited by 3,336
Regression analysis of multivariate incomplete failure time data by modeling marginal distributions
Wei, L. J., Lin, D. Y., & Weissfeld, L. (1989) · Journal of the American Statistical Association · doi:10.1080/01621459.1989.10478873 · Cited by 1,868
Schmechel, D. E., Saunders, A. M., Strittmatter, W. J., Crain, B. J., Hulette, C. M., Joo, S. H., Pericak-Vance, M. A., Goldgaber, D., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.20.9649 · Cited by 1,525
Self-citationThe Genetic Defect Causing Familial Alzheimer's Disease Maps on Chromosome 21
St George-Hyslop, P. H., Tanzi, R. E., Polinsky, R. J., Haines, J. L., Nee, L., Watkins, P. C., Myers, R. H., Feldman, R. G., Pollen, D., Drachman, D., et al. (1987) · Science · doi:10.1126/science.2880399 · Cited by 1,163
Self-citationNamba, Y., Tomonaga, M., Kawasaki, H., Otomo, E., & Ikeda, K. (1991) · Brain Research · doi:10.1016/0006-8993(91)91092-f · Cited by 1,157
Genetic Linkage Evidence for a Familial Alzheimer's Disease Locus on Chromosome 14
Schellenberg, G. D., Bird, T. D., Wijsman, E. M., Orr, H. T., Anderson, L., Nemens, E., White, J. A., Bonnycastle, L., Weber, J. L., Alonso, M. E., et al. (1992) · Science · doi:10.1126/science.1411576 · Cited by 946
Research works printed but not linked: 3
- SAS/STAT User's Guide Release 6.03 Edition (1988).
- SAS User's Guide: Statistics Version 5 Edition (1985).
- 10.1073/pnas.90.5.1977 · DOI · Paper page
Cited by
Items 1,001–1,100 of 1,689
Genetics ignite focus on microglial inflammation in Alzheimer’s disease
Malik, M., Parikh, I., Vasquez, J. B., Smith, C., Tai, L., Bu, G., LaDu, M. J., Fardo, D. W., Rebeck, G. W., & Estus, S. (2015) · Molecular Neurodegeneration · doi:10.1186/s13024-015-0048-1 · Cited by 161
“Of the three common APOE alleles, APOE4 raises AD risk and reduces age of AD onset, while APOE2 lowers AD risk and increases age of onset [125].”
BackgroundProtas, H. D., Chen, K., Langbaum, J. B. S., Fleisher, A. S., Alexander, G. E., Lee, W., Bandy, D., de Leon, M. J., Mosconi, L., Buckley, S., et al. (2013) · JAMA Neurology · doi:10.1001/2013.jamaneurol.286 · Cited by 161
“Each additional ε4 allele in a person’s APOE genotype is associated with a greater risk of AD and a younger average age at clinical onset.(26) We and others have found that cognitively normal, late-middle-aged and young adult APOE ε4 carriers exhibit CMRgl reductions in these AD-affected regions(7-9,27,28) and that th…”
BackgroundInfluentialLoss of the neuroprotective factor sphingosine 1-phosphate early in Alzheimer’s disease pathogenesis
Couttas, T. A., Kain, N., Daniels, B., Lim, X. Y., Shepherd, C., Kril, J., Pickford, R., Li, H., Garner, B., & Don, A. S. (2014) · Acta Neuropathologica Communications · doi:10.1186/2051-5960-2-9 · Cited by 161
“allele have a 12-fold increased risk of developing AD, compared with non-carriers [12].”
BackgroundThe apolipoprotein E varepsilon2 allele and decline in episodic memory
Wilson, R. S. (2002) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.73.6.672 · Cited by 161
Fryer, J. D., Taylor, J. W., DeMattos, R. B., Bales, K. R., Paul, S. M., Parsadanian, M., & Holtzman, D. M. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-21-07889.2003 · Cited by 160
“In 1993 the 4 allele of APOE was shown to be a genetic risk factor for developing AD (Corder et al., 1993; Rebeck et al., 1993; Strittmatter et al., 1993) and subsequently also found to be a risk factor for CAA (Schmechel et al.”
BackgroundKalback, W., Esh, C., Castaño, E. M., Rahman, A., Kokjohn, T., Luehrs, D. C., Sue, L., Cisneros, R., Gerber, F., Richardson, C., et al. (2004) · Neurological Research · doi:10.1179/016164104225017668 · Cited by 160
Understanding the association of apolipoprotein E4 with Alzheimer disease: clues from its structure
Zhong, N., & Weisgraber, K. H. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.r800009200 · Cited by 159
Coskun, P. E., Wyrembak, J., Derbereva, O., Melkonian, G., Doran, E., Lott, I. T., Head, E., Cotman, C. W., & Wallace, D. C. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-100351 · Cited by 159
“(PSEN1), and presenillin2 (PSEN2) gene mutations, mutations in these genes account for less than 5% of AD cases [1–7].”
Duan, L., Bhattacharyya, B. J., Belmadani, A., Pan, L., Miller, R. J., & Kessler, J. A. (2014) · Molecular Neurodegeneration · doi:10.1186/1750-1326-9-3 · Cited by 159
“As a major risk factor in sporadic AD, the ApoE4 allele is associated with earlier onset and increased amyloid plaques in AD [37-39].”
BackgroundMore than cholesterol transporters: lipoprotein receptors in CNS function and neurodegeneration
Lane-Donovan, C., Philips, G. T., & Herz, J. (2014) · Neuron · doi:10.1016/j.neuron.2014.08.005 · Cited by 158
“Relative to ApoE3, ApoE4 is present in approximately 15%– 20% of the population and is associated with greatly increased risk and earlier onset of AD (Corder et al., 1993; Schmechel et al., 1993).”
Carlson, G. A., Borchelt, D. R., Dake, A., Turner, S., Danielson, V., Coffin, J. D., Eckman, C., Meiners, J., Nilsen, S. P., Younkin, S. G., et al. (1997) · Human Molecular Genetics · doi:10.1093/hmg/6.11.1951 · Cited by 158
Profile of cholesterol-related sterols in aged amyloid precursor protein transgenic mouse brain
Lütjohann, D., Brzezinka, A., Barth, E., Abramowski, D., Staufenbiel, M., von Bergmann, K., Beyreuther, K., Multhaup, G., & Bayer, T. A. (2002) · Journal of Lipid Research · doi:10.1194/jlr.m200071-jlr200 · Cited by 158
“The 4 allele of apoE is the major known genetic risk factor for sporadic AD (6).”
Ohm, T. G., Kirca, M., Bohl, J., Scharnagl, H., Groβ, W., & März, W. (1995) · Neuroscience · doi:10.1016/0306-4522(94)00596-w · Cited by 157
Hartman, R. E., Wozniak, D. F., Nardi, A., Olney, J. W., Sartorius, L., & Holtzman, D. M. (2001) · Experimental Neurology · doi:10.1006/exnr.2001.7715 · Cited by 157
The involvement of lipid rafts in Alzheimer's disease (Review)
Cordy, J. M., Cordy, J. M., Hooper, N. M., & Turner, A. J. (2006) · Molecular Membrane Biology · doi:10.1080/09687860500496417 · Cited by 157
“Individuals carrying the o4 allele of apoE have an increased risk of developing AD (Seshadri et al. 1995) and show a lower average age of onset of the disease (Corder et al. 1993; Strittmatter & Roses 1995).”
BackgroundInfluentialAnthony, I. C., Norrby, K. E., Dingwall, T., Carnie, F. W., Millar, T., Arango, J. C., Robertson, R., & Bell, J. E. (2010) · Brain · doi:10.1093/brain/awq263 · Cited by 156
Plasma levels of apolipoprotein Eand risk of dementia in the general population
Rasmussen, K. L., Tybjærg‐Hansen, A., Nordestgaard, B. G., & Frikke‐Schmidt, R. (2015) · Annals of Neurology · doi:10.1002/ana.24326 · Cited by 156
APOE4-mediated amyloid-β pathology depends on its neuronal receptor LRP1
Tachibana, M., Holm, M.-L., Liu, C.-C., Shinohara, M., Aikawa, T., Oue, H., Yamazaki, Y., Martens, Y. A., Murray, M. E., Sullivan, P. M., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci124853 · Cited by 156
A Genomewide Screen for Late-Onset Alzheimer Disease in a Genetically Isolated Dutch Population
Liu, F., Arias-Vásquez, A., Sleegers, K., Aulchenko, Y. S., Kayser, M., Sanchez-Juan, P., Feng, B.-J., Bertoli-Avella, A. M., van Swieten, J., Axenovich, T. I., et al. (2007) · The American Journal of Human Genetics · doi:10.1086/518720 · Cited by 156
“A common polymorphism ( 4) in the gene encoding apolipoprotein E (APOE [MIM 107741]) increases susceptibility to both early- and late-onset AD.(8,9) These four genes together explain less than a quarter of the disease prevalence, indicating that additional genetic risk factors remain to be identified.”
BackgroundInfluentialChalmers, K., Wilcock, G. K., & Love, S. (2003) · Neuropathology and Applied Neurobiology · doi:10.1046/j.1365-2990.2003.00457.x · Cited by 156
Formation and function of apolipoprotein E-containing lipoproteins in the nervous system
Vance, J. E., & Hayashi, H. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2010.02.007 · Cited by 155
Sanders, L. M. J., Hortobágyi, T., Karssemeijer, E. G. A., Van der Zee, E. A., Scherder, E. J. A., & van Heuvelen, M. J. G. (2020) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-00597-3 · Cited by 154
“For example, the presence of the apolipoprotein-E4 (ApoE4) allele, a risk factor for Alzheimer’s disease (AD) [29], may mediate the magnitude of exercise effects.”
BackgroundCholesterol metabolism in Huntington disease
Karasinska, J. M., & Hayden, M. R. (2011) · Nature Reviews Neurology · doi:10.1038/nrneurol.2011.132 · Cited by 154
Liver X receptor activation restores memory in aged AD mice without reducing amyloid
Vanmierlo, T., Rutten, K., Dederen, J., Bloks, V. W., van Vark-van der Zee, L. C., Kuipers, F., Kiliaan, A., Blokland, A., Sijbrands, E. J. G., Steinbusch, H., et al. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.07.005 · Cited by 154
Reelin signaling antagonizes β-amyloid at the synapse
Durakoglugil, M. S., Chen, Y., White, C. L., Kavalali, E. T., & Herz, J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0908176106 · Cited by 153
Alzheimer's Disease Genetics Consortium, Wetzel-Smith, M. K., Hunkapiller, J., Bhangale, T. R., Srinivasan, K., Maloney, J. A., Atwal, J. K., Sa, S. M., B Yaylaoglu, M., Foreman, O., et al. (2014) · Nature Medicine · doi:10.1038/nm.3736 · Cited by 153
Self-citationEpigenetics in Alzheimer’s Disease: Perspective of DNA Methylation
Qazi, T. J., Quan, Z., Mir, A., & Qing, H. (2018) · Molecular Neurobiology · doi:10.1007/s12035-016-0357-6 · Cited by 153
The APOE ɛ4 allele modulates brain white matter integrity in healthy adults
Heise, V, Filippini, N., Ebmeier, K. P., & Mackay, C. E. (2011) · Molecular Psychiatry · doi:10.1038/mp.2010.90 · Cited by 152
Accelerated decline in apolipoprotein E-ϵ4 homozygotes with Alzheimer's disease
Craft, S., Teri, L., Edland, S. D., Kukull, W. A., Schellenberg, G., McCormick, W. C., Bowen, J. D., & Larson, E. B. (1998) · Neurology · doi:10.1212/wnl.51.1.149 · Cited by 152
The Important Interface Between Apolipoprotein E and Neuroinflammation in Alzheimer’s Disease
Kloske, C. M., & Wilcock, D. M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00754 · Cited by 152
Harris, F. M., Brecht, W. J., Xu, Q., Mahley, R. W., & Huang, Y. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m408127200 · Cited by 151
Fitz, N. F., Cronican, A. A., Lefterov, I., & Koldamova, R. (2013) · Science · doi:10.1126/science.1235809 · Cited by 151
Dissecting the clinical heterogeneity of early-onset Alzheimer’s disease
Sirkis, D. W., Bonham, L. W., Johnson, T. P., La Joie, R., & Yokoyama, J. S. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01531-9 · Cited by 151
“Although the ε 4 allele was initially associated with LOAD, given that it is known to reduce the age at onset (AAO) [170], it is not surprising that this variant also increases risk for EOAD [174, 175].”
InfluentialApolipoprotein E Genetic Variation and Alzheimer’s Disease
Rubinsztein, D. C., & Easton, D. F. (1999) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000017120 · Cited by 151
Longitudinal brain imaging in preclinical Alzheimer disease: impact of APOE ε4 genotype
Mishra, S., Blazey, T. M., Holtzman, D. M., Cruchaga, C., Su, Y., Morris, J. C., Benzinger, T. L. S., & Gordon, B. A. (2018) · Brain · doi:10.1093/brain/awy103 · Cited by 151
Meng, X.-F., Yu, J.-T., Wang, H.-F., Tan, M.-S., Wang, C., Tan, C.-C., & Tan, L. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-140954 · Cited by 150
“Although the effect of each separate VRF was modest compared to the genetic risk of carrying the APOE4 allele [43, 44], the high prevalence of these disorders may lead to the increase of the incidence of AD in the decades to come.”
APOE-ε2 and APOE-ε4 Correlate With Increased Amyloid Accumulation in Cerebral Vasculature
Nelson, P. T., Pious, N. M., Jicha, G. A., Wilcock, D. M., Fardo, D. W., Estus, S., & Rebeck, G. W. (2013) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31829a25b9 · Cited by 150
Common Variants in Psychiatric Risk Genes Predict Brain Structure at Birth
Knickmeyer, R. C., Wang, J., Zhu, H., Geng, X., Woolson, S., Hamer, R. M., Konneker, T., Lin, W., Styner, M., & Gilmore, J. H. (2014) · Cerebral Cortex · doi:10.1093/cercor/bhs401 · Cited by 149
A pooled case-control study of the apolipoprotein E (APOE) gene in age-related maculopathy
Schmidt, S., Klaver, C. C. W., Saunders, A. M., Postel, E. A., De La Paz, M. A., Agarwal, A., Small, K. W., Udar, N., Ong, J. M., Chalukya, M. V., et al. (2002) · Ophthalmic Genetics · doi:10.1076/opge.23.4.209.13883 · Cited by 149
Self-citationFlowers, S. A., & Rebeck, G. W. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104724 · Cited by 149
Frisoni, G. B., Govoni, S., Geroldi, C., Bianchetti, A., Calabresi, L., Franceschini, G., & Trabucchi, M. (1995) · Annals of Neurology · doi:10.1002/ana.410370509 · Cited by 149
Tolar, M., Keller, J. N., Chan, S., Mattson, M. P., Marques, M. A., & Crutcher, K. A. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-16-07100.1999 · Cited by 148
“…by the association between inheritance of the allele for the E4 isoform of apoE and the increased risk and earlier age of onset of the disease (Corder et al., 1993; Saunders et al., 1993a,b; Strittmatter et al., 1993), as well as immunohistochemical localization of apoE to senile plaques and…”
Grootendorst, J., Bour, A., Vogel, E., Kelche, C., Sullivan, P. M., Dodart, J.-C., Bales, K., & Mathis, C. (2005) · Behavioural Brain Research · doi:10.1016/j.bbr.2004.09.019 · Cited by 148
Tzioras, M., Davies, C., Newman, A., Jackson, R., & Spires‐Jones, T. (2019) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12529 · Cited by 147
Transgenic mouse models of Alzheimer's disease: phenotype and application.
(2003) · PubMed · doi:10.1097/01.fbp.0000088420.18414.ff · Cited by 147
“…these preclinical data are consistent with the observation that individuals carrying one or two ApoE4 alleles are more likely to develop AD (Corder et al., 1993), and have poorer outcome and higher plaque burden following traumatic brain injury (Mayeux et al., 1995; Nicoll et al., 1995),…”
BackgroundResultInfluentialA molecular pathway of neurodegeneration linking α-synuclein to ApoE and Aβ peptides
Gallardo, G., Schlüter, O. M., & Südhof, T. C. (2008) · Nature Neuroscience · doi:10.1038/nn2058 · Cited by 145
Haass, C., & Selkoe, D. (2022) · PLOS Biology · doi:10.1371/journal.pbio.3001694 · Cited by 145
“ApoE comes in 3 variants, ApoE2, ApoE3, and ApoE4, of which ApoE4 considerably increases the risk for sporadic (late onset) AD [58].”
BackgroundATP-binding cassette transporter A1: From metabolism to neurodegeneration
Koldamova, R., Fitz, N. F., & Lefterov, I. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.05.007 · Cited by 144
Apolipoprotein E controls the risk and age at onset of Parkinson disease
Li, Y. J., Hauser, M. A., Scott, W. K., Martin, E. R., Booze, M. W., Qin, X. J., Walter, J. W., Nance, M. A., Hubble, J. P., Koller, W. C., et al. (2004) · Neurology · doi:10.1212/01.wnl.0000128089.53030.ac · Cited by 144
“APOE-44 20 (23) 3 (4) 17 (19) 12 (16) 8 (7) 1 (1)”
Self-citationStem cell models of Alzheimer’s disease: progress and challenges
Arber, C., Lovejoy, C., & Wray, S. (2017) · Alzheimer's Research & Therapy · doi:10.1186/s13195-017-0268-4 · Cited by 143
“The APOE4 variant was initially identified in 1993 as an AD risk factor [83].”
Lane, R. F., Raines, S. M., Steele, J. W., Ehrlich, M. E., Lah, J. A., Small, S. A., Tanzi, R. E., Attie, A. D., & Gandy, S. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.3872-10.2010 · Cited by 143
“…genes, including several that belong to one of three classes of molecules: (1) the apolipoprotein family, the most notable, apolipoprotein E (APOE) (Corder et al., 1993; Saunders et al., 1993); (2) the low-density lipoprotein receptor (LDLR) family (Kang et al., 1997; Lendon et al., 1997); and…”
BackgroundFilippini, N., Rao, A., Wetten, S., Gibson, R. A., Borrie, M., Guzman, D., Kertesz, A., Loy-English, I., Williams, J., Nichols, T., et al. (2009) · NeuroImage · doi:10.1016/j.neuroimage.2008.10.003 · Cited by 143
“, 2001), just as increasing APOE ɛ4 allele load is associated with earlier age of onset (Corder et al., 1993).”
BackgroundResultInfluentialHoltzman, D. M. (2001) · Journal of Molecular Neuroscience · doi:10.1385/jmn:17:2:147 · Cited by 143
“…to this study, numerous studies have confirmed that the ε4 allele is an AD risk factor (particularly in the age range of 60–80) and that the ε2 allele appears to be protective against AD (Corder et al., 1993; Mayeux et al., 1993; Corder et al., 1994; Poirer, 1994; Strittmatter and Roses, 1996).”
BackgroundBeffert, U., Cohn, J. S., Petit-Turcotte, C., Tremblay, M., Aumont, N., Ramassamy, C., Davignon, J., & Poirier, J. (1999) · Brain Research · doi:10.1016/s0006-8993(99)01894-6 · Cited by 142
Neuronal apolipoprotein E4 increases cell death and phosphorylated tau release in alzheimer disease
Wadhwani, A. R., Affaneh, A., Van Gulden, S., & Kessler, J. A. (2019) · Annals of Neurology · doi:10.1002/ana.25455 · Cited by 142
“The apolipoprotein E (APOE) E4 allele, the strongest genetic risk factor for sporadic Alzheimer disease (AD), differs from the risk-neutral E3 allele by a single nucleotide polymorphism (SNP).(1,2) E4 patients exhibit greater brain atrophy, accumulation of hyperphosphorylated tau protein, and deposition of amyloid, al…”
BackgroundKim, J., Yoon, H., Basak, J., & Kim, J. (2014) · Molecules and Cells · doi:10.14348/molcells.2014.0248 · Cited by 164
“Rare apoE2 allele has a protective effect against LOAD compared to other alleles (Corder et al., 1993).”
BackgroundAnalysis of the MIRIAD Data Shows Sex Differences in Hippocampal Atrophy Progression
Ardekani, B. A., Convit, A., & Bachman, A. H. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-150780 · Cited by 141
Bour, A., Grootendorst, J., Vogel, E., Kelche, C., Dodart, J.-C., Bales, K., Moreau, P.-H., Sullivan, P. M., & Mathis, C. (2008) · Behavioural Brain Research · doi:10.1016/j.bbr.2008.05.008 · Cited by 141
Genetic and epigenetic regulation of human aging and longevity
Morris, B. J., Willcox, B. J., & Donlon, T. A. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.08.039 · Cited by 140
Holstege, H., van der Lee, S. J., Hulsman, M., Wong, T. H., van Rooij, J. G., Weiss, M., Louwersheimer, E., Wolters, F. J., Amin, N., Uitterlinden, A. G., et al. (2017) · European Journal of Human Genetics · doi:10.1038/ejhg.2017.87 · Cited by 140
Mahan, T. E., Wang, C., Bao, X., Choudhury, A., Ulrich, J. D., & Holtzman, D. M. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00516-0 · Cited by 134
“The influence of APOE on AD risk occurs in an isoform-dependent manner (ε2 ε3 ε4) [3–6].”
BackgroundFryer, J. D., DeMattos, R. B., McCormick, L. M., O'Dell, M. A., Spinner, M. L., Bales, K. R., Paul, S. M., Sullivan, P. M., Parsadanian, M., Bu, G., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m502143200 · Cited by 139
Loss‐of‐function mutation in ABCA1 and risk of Alzheimer's disease and cerebrovascular disease
Nordestgaard, L. T., Tybjærg‐Hansen, A., Nordestgaard, B. G., & Frikke‐Schmidt, R. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.04.006 · Cited by 139
“The validity of AD ICD codes was ensured by the presence of the well-known association with ε4 in the present cohort [23], with a 7–8 fold risk for homozygotes for the ε4 allele versus the most common genotype, similar to risk estimates reported elsewhere [3,24].”
Grehan, S., Tse, E., & Taylor, J. M. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-03-00812.2001 · Cited by 138
“ApoE4 is an important risk factor for late-onset Alzheimer’s disease (Corder et al., 1993; Strittmatter et al., 1993; Roses, 1996).”
BackgroundAleshkov, S., Abraham, C. R., & Zannis, V. I. (1997) · Biochemistry · doi:10.1021/bi9626362 · Cited by 138
Cruchaga, C., Del‐Aguila, J. L., Saef, B., Black, K., Fernandez, M. V., Budde, J., Ibanez, L., Deming, Y., Kapoor, M., Tosto, G., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2017.08.013 · Cited by 138
“The apolipoprotein E (APOE) ε4 allele increases risk for sEOAD, sLOAD [6], and also for fLOAD [7,10] (3-fold effect size for heterozygous carriers and 12-fold for homozygous carriers [11,12]).”
BackgroundNilsson, L. N. G., Bales, K. R., DiCarlo, G., Gordon, M. N., Morgan, D., Paul, S. M., & Potter, H. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-05-01444.2001 · Cited by 137
“, 1998), and the ApoE coding regions (Corder et al., 1993; Strittmatter et al., 1993) as well as the ApoE promoter (Bullido et”
BackgroundAPOE genotype and stress response - a mini review
Dose, J., Huebbe, P., Nebel, A., & Rimbach, G. (2016) · Lipids in Health and Disease · doi:10.1186/s12944-016-0288-2 · Cited by 137
“More obvious, the ε4 allele increases the risk and decreases the age of onset of late-onset Alzheimer’s disease (AD) in a dose-dependent manner [51].”
BackgroundLow-Density Lipoprotein Receptor Family
Bu, G., Li, Y., & Cam, J. (2001) · Molecular Neurobiology · doi:10.1385/mn:23:1:53 · Cited by 137
“Carriers of the E4 isoform of apoE are at a greater risk for developing AD (78,79), compared to E2 and E3 carriers.”
BackgroundOxidant/antioxidant imbalance and the risk of Alzheimer's disease
Moneim, A. (2015) · Current Alzheimer Research · doi:10.2174/1567205012666150325182702 · Cited by 136
“The three forms of ApoE are ApoE ε2, ApoE ε3, and ApoE ε4 [7].”
APOE-by-sex interactions on brain structure and metabolism in healthy elderly controls
Sampedro, F., Initiative, F. T. A. D. N., Vilaplana, E., de Leon, M. J., Alcolea, D., Pegueroles, J., Montal, V., Carmona-Iragui, M., Sala, I., Sánchez-Saudinos, M.-B., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5185 · Cited by 135
Protective genes and pathways in Alzheimer’s disease: moving towards precision interventions
Seto, M., Weiner, R. L., Dumitrescu, L., & Hohman, T. J. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00452-5 · Cited by 135
Qin, S., Colin, C., Hinners, I., Gervais, A., Cheret, C., & Mallat, M. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.5186-05.2006 · Cited by 135
“Whereas the E2 allele is associated with a decreased risk of AD, the E4 allele increases the risk (Corder et al., 1993, 1994).”
BackgroundAstroglial Regulation of Apolipoprotein E Expression in Neuronal Cells
Harris, F. M., Tesseur, I., Brecht, W. J., Xu, Q., Mullendorff, K., Chang, S., Wyss-Coray, T., Mahley, R. W., & Huang, Y. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m309475200 · Cited by 135
Reversal of apoE4-driven brain pathology and behavioral deficits by bexarotene
Boehm-Cagan, A., & Michaelson, D. M. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.5198-13.2014 · Cited by 134
“Genetic studies of Alzheimer’s disease (AD) revealed allelic segregation of the apoE gene to sporadic AD and to families with a higher risk of late-onset AD (Corder et al., 1993; Saunders et al., 1993; Roses, 1996).”
BackgroundThal, D. R., Griffin, W. S. T., & Braak, H. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00411.x · Cited by 134
“However, only four genes are widely proven for their influence on AD pathology: APP, PS1, PS2 and APOE [139–145].”
BackgroundJi, Z.-S., Pitas, R. E., & Mahley, R. W. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.22.13452 · Cited by 134
Biology of Aβ Amyloid in Alzheimer's Disease
Wisniewski, T., Ghiso, J., & Frangione, B. (1997) · Neurobiology of Disease · doi:10.1006/nbdi.1997.0147 · Cited by 134
Frieden, C., Wang, H., & Ho, C. M. W. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1705080114 · Cited by 134
“ApoE4 is the most studied since, relative to apoE3, it is known to be the major risk factor for the development of late-onset Alzheimer’s disease (2, 3), whereas apoE2, the less common form, is associated with type III hyperlipoproteinemia (4, 5).”
BackgroundTau and Axonopathy in Neurodegenerative Disorders
Higuchi, M., Lee, V. M.-Y., & Trojanowski, J. Q. (2002) · NeuroMolecular Medicine · doi:10.1385/nmm:2:2:131 · Cited by 134
The endocytic pathway in microglia during health, aging and Alzheimer’s disease
Solé-Domènech, S., Cruz, D. L., Capetillo-Zarate, E., & Maxfield, F. R. (2016) · Ageing Research Reviews · doi:10.1016/j.arr.2016.07.002 · Cited by 133
Ghebremedhin, E., Schultz, C., Braak, E., & Braak, H. (1998) · Experimental Neurology · doi:10.1006/exnr.1998.6860 · Cited by 133
Ramanan, V. K., Risacher, S. L., Nho, K., Kim, S., Shen, L., McDonald, B. C., Yoder, K. K., Hutchins, G. D., West, J. D., Tallman, E. F., et al. (2015) · Brain · doi:10.1093/brain/awv231 · Cited by 133
“For late-onset Alzheimer’s disease, the strongest known genetic risk factor is the APOE "4 allele (Corder et al., 1993).”
BackgroundFrieden, C., & Garai, K. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1207022109 · Cited by 133
Neuronal APOE4 removal protects against tau-mediated gliosis, neurodegeneration and myelin deficits
Koutsodendris, N., Blumenfeld, J., Agrawal, A., Traglia, M., Grone, B., Zilberter, M., Yip, O., Rao, A., Nelson, M. R., Hao, Y., et al. (2023) · Nature Aging · doi:10.1038/s43587-023-00368-3 · Cited by 132
Animal models of Alzheimer disease: historical pitfalls and a path forward
Cavanaugh, S. E. (2014) · ALTEX · doi:10.14573/altex.1310071 · Cited by 132
“Inheritance of the apolipoprotein E type 4 allele (ApoE4) may increase the risk of developing sporadic late-onset AD, though ApoE4 alone is neither necessary nor sufficient to cause AD (Strittmatter et al., 1993; Corder et al., 1993; Sadigh-Eteghad et al., 2012; Rossor et al., 1996).”
Mahley, R. W., & Huang, Y. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm3008618 · Cited by 132
ApoE immunoreactivity and microglial cells in Alzheimer’s disease brain
Uchihara, T., Duyckaerts, C., He, Y., Kobayashi, K., Seilhean, D., Amouyel, P., & Hauw, J.-J. (1995) · Neuroscience Letters · doi:10.1016/0304-3940(95)11763-m · Cited by 131
APOE-amyloid interaction: Therapeutic targets
Wisniewski, T., & Drummond, E. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104784 · Cited by 131
The Future of Precision Medicine in the Cure of Alzheimer’s Disease
Arafah, A., Khatoon, S., Rasool, I., Khan, A., Rather, M. A., Abujabal, K. A., Faqih, Y. A. H., Rashid, H., Rashid, S. M., Bilal Ahmad, S., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11020335 · Cited by 133
“In particular, the E4 allele has been connected to an increased risk of AD [62], while there is less risk linked with the E2 allele [63].”
BackgroundMartins, R. N., Villemagne, V., Sohrabi, H. R., Chatterjee, P., Shah, T. M., Verdile, G., Fraser, P., Taddei, K., Gupta, V. B., Rainey-Smith, S. R., et al. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-171145 · Cited by 129
The pursuit of susceptibility genes for Alzheimer's disease: progress and prospects
Sleegers, K., Lambert, J.-C., Bertram, L., Cruts, M., Amouyel, P., & Van Broeckhoven, C. (2010) · Trends in Genetics · doi:10.1016/j.tig.2009.12.004 · Cited by 129
LANGE, K. L., BONDI, M. W., SALMON, D. P., GALASKO, D., DELIS, D. C., THOMAS, R. G., & THAL, L. J. (2002) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617702870096 · Cited by 129
“…E. Apolipoprotein E is a cholesterol-transporting protein coded on chromosome 19 by a polymorphic gene with three common allele types: e2, e3, ande4, resulting in six possible genotypes:e202, e203,e204,e303,e304, ande404 (Corder et al., 1993; Saunders et al., 1993; Strittmatter et al., 1993).”
BackgroundFitz, N. F., Nam, K. N., Wolfe, C. M., Letronne, F., Playso, B. E., Iordanova, B. E., Kozai, T. D. Y., Biedrzycki, R. J., Kagan, V. E., Tyurina, Y. Y., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23762-0 · Cited by 129
Liao, F., Hori, Y., Hudry, E., Bauer, A. Q., Jiang, H., Mahan, T. E., Lefton, K. B., Zhang, T. J., Dearborn, J. T., Kim, J., et al. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.0646-14.2014 · Cited by 147
“The 4 allele of apolipoprotein E (apoE) has been established as the strongest genetic risk factor for late-onset AD (Corder et al., 1993; Strittmatter et al., 1993a; Strittmatter et al., 1993b; Corder et al., 1994; Belinson and Michaelson, 2009).”
BackgroundThe Inflammatory Continuum of Traumatic Brain Injury and Alzheimer’s Disease
Kokiko-Cochran, O. N., & Godbout, J. P. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00672 · Cited by 128
Reactivity of Apolipoprotein E4 and Amyloid β Peptide
Ji, Z.-S., Müllendorff, K., Cheng, I. H., Miranda, R. D., Huang, Y., & Mahley, R. W. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m506646200 · Cited by 127
Examination of the current top candidate genes for AD in a genome-wide association study
Feulner, T. M., Laws, S. M., Friedrich, P., Wagenpfeil, S., Wurst, S. H. R., Riehle, C., Kuhn, K. A., Krawczak, M., Schreiber, S., Nikolaus, S., et al. (2010) · Molecular Psychiatry · doi:10.1038/mp.2008.141 · Cited by 128
The selection landscape and genetic legacy of ancient Eurasians
Irving-Pease, E. K., Refoyo-Martínez, A., Barrie, W., Ingason, A., Pearson, A., Fischer, A., Sjögren, K.-G., Halgren, A. S., Macleod, R., Demeter, F., et al. (2024) · Nature · doi:10.1038/s41586-023-06705-1 · Cited by 126
“We focused on 35 phenotypes whose polygenic scores were significantly overdispersed among the ancient populations (Supplementary Note 9), as well as well as three large effect alleles at the APOE gene (ApoE2, ApoE3 and ApoE4) known to significantly mediate risk of developing Alzheimer’s disease 86 .”
BackgroundGenetic architecture of Alzheimer's disease
Neuner, S. M., TCW, J., & Goate, A. M. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104976 · Cited by 126
Metadata
- Authors
- Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A.
- Affiliations
- Duke University (US)
- Duke Medical Center (US)
- University of California, Los Angeles (US)
- Massachusetts General Hospital (US)
- Joseph and Kathleen Bryan Alzheimer's Disease Research Center, Duke University Medical Center, Durham, NC 27710.
- Venue
- Science
- Published
- 1993-08-13
- Volume
- 261
- Issue
- 5123
- Pages
- 921-923
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2036362108
- Cited by
- 9,429
- References
- 16
- Citations by year
- 2026: 289 · 2025: 380 · 2024: 355 · 2023: 328 · 2022: 356 · 2021: 378 · 2020: 396 · 2019: 358 · 2018: 341 · 2017: 343 · 2016: 345 · 2015: 303 · 2014: 343 · 2013: 335 · 2012: 333
- FWCI
- 135.93
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- apolipoprotein E, APOE ε4, gene dosage, Alzheimer's disease, genetic risk, homozygosity, age of onset, genetic association
- MeSH terms
- Aged, Aged, 80 and over, Aging, Alleles, Alzheimer Disease, Apolipoproteins E, Female, Gene Frequency, Genotype, Homozygote, Humans, Male, Risk Factors, Linkage Disequilibrium, Survival Rate, Amyloid beta-Peptides, Apolipoprotein E4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.